Sareum Holdings plc (LON:SAR – Get Free Report)’s stock price crossed above its 50 day moving average during trading on Monday . The stock has a 50 day moving average of GBX 21.85 and traded as high as GBX 24. Sareum shares last traded at GBX 22.46, with a volume of 207,124 shares.
Sareum Price Performance
The business’s fifty day simple moving average is GBX 21.85 and its 200 day simple moving average is GBX 18.91. The stock has a market cap of £31.12 million, a price-to-earnings ratio of -5.76 and a beta of -1.08.
About Sareum
Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the ‘cytokine storm’ immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).
Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms.
Featured Articles
- Five stocks we like better than Sareum
- The SK Hynix IPO and 2027’s AI Memory Squeeze
- Meta Platforms Stock Rises as Muse Spark 1.1 AI Model Debuts
- Why Welltower’s Growth Story Might Outrun Its Rich Valuation
- One Short- and One Long-Term ETF for Quantum Computing Bulls
Receive News & Ratings for Sareum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sareum and related companies with MarketBeat.com's FREE daily email newsletter.
